Eva Dahlen | Principal Scientist and Director Business Development
Alligator Bioscience AB

Eva Dahlen, Principal Scientist and Director Business Development, Alligator Bioscience AB

Dr. Dahlén is Senior Director, Business Development at Alligator Bioscience. Her main responsibilities include scientific business development, competitive intelligence and establishment of partnerships. In biotech and academia partnerships Alligator´s immuno-oncology pipeline is strengthened by accessing technologies complementing Alligator´s in-house capabilities, whereas pharma partnerships are established for late phases of clinical development and commercialization. Previous positions at Alligator include principal scientist and project leader in various drug discovery and research programs in the field of immuno-oncology, and earlier affiliations are Malmö university, Lund university and Active Biotech.

Appearances:



Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 15:30

Superior safety and efficacy by tumour-directed immunotherapy

  • Tumor-directed immunotherapies are designed to primarily activate the tumor-specific immune cells infiltrating tumors
  • Tumor-localized immune activation results in a favourable safety/efficacy profile compared to systemic immunotherapy
  • Mono- and bispecific antibody-based drug candidates exhibiting tumor-directed immunostimulation and anti-tumor effects will be discussed

back to speakers

World Advanced Therapies & Regenerative Medicine Congress

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com